Two different Rac1 inhibitors displayed anti-angiogenic activity in breast cancer models in vivo [66,67] supporting a potential benefit of Rac1 inhibition as an alternate anti-angiogenic strategy in cancer, including ovarian cancer. Here, RAC1 is linked to ovarian cancer.